La visión del IOZK: poner en práctica de forma oportuna los resultados de la investigación inmuno-oncológica
El Dr. Wilfried Stücker es Director General del IOZK y de la Fundación IOZK. En 1985 puso en marcha el actual Centro Inmuno-Oncológico de Colonia. En colaboración con varios médicos y científicos, desarrolló la inmunoterapia del IOZK y creó el centro de tratamiento con los laboratorios.
La Fundación IOZK se creó en 2019 para optimizar las inmunoterapias contra el cáncer.
"Prolongar la vida de los enfermos de cáncer y ofrecerles tratamientos suaves es a lo que nos dedicamos en el IOZK con nuestra experiencia".
Dr. Wilfried Stücker
Colección: Contribuciones científicas y publicaciones internacionales del Dr. Wilfried Stücker
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002023-07-28 / Transl Cancer Res 2023 Aug;12(8):2224-2228https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2023-07-28 / Transl Cancer Res 2023 Aug;12(8):2224-22282023-07-28 00:00:002024-04-17 15:08:24Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002023-06-23 / Biomedicines 2023 Jun;11(7)https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2023-06-23 / Biomedicines 2023 Jun;11(7)2023-06-23 00:00:002024-04-17 15:04:06The Application of Evidence-Based Medicine in Individualized Medicine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002023-02-13 / Cancers (Basel) 2023 Feb;15(4)https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2023-02-13 / Cancers (Basel) 2023 Feb;15(4)2023-02-13 00:00:002023-05-30 16:20:40Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002022-02-28 / Biomedicines 2022 Feb;10(3)https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2022-02-28 / Biomedicines 2022 Feb;10(3)2022-06-02 00:00:002025-03-27 05:35:20Posterpräsentation auf der Jahrestagung der Association for Cancer Immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002021-07-04 / Cancer Immunol Immunother 2021 Jul;https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2021-07-04 / Cancer Immunol Immunother 2021 Jul;2021-07-04 00:00:002021-11-15 12:29:15Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002020-05-19 / Medicines (Basel) 2020 May;7(5)https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2020-05-19 / Medicines (Basel) 2020 May;7(5)2020-05-19 00:00:002021-11-15 20:10:42Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002019-08-30 / Biomedicines 2019 Aug;7(3)https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2019-08-30 / Biomedicines 2019 Aug;7(3)2019-08-30 00:00:002021-11-15 13:22:59Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002015-05-28 / Immunotherapy 2015;7(8):855-60https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2015-05-28 / Immunotherapy 2015;7(8):855-602015-05-28 00:00:002021-11-16 07:55:05Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002014-10-06 / Oncol Lett 2014 Dec;8(6):2403-2406https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2014-10-06 / Oncol Lett 2014 Dec;8(6):2403-24062014-10-06 00:00:002021-11-16 07:53:33Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report
The Complexity of Malignant Glioma Treatment
Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution
Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients
Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?
The Application of Evidence-Based Medicine in Individualized Medicine
Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
Presentación de un póster en la reunión anual de la Asociación para la Inmunoterapia del Cáncer
Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors
Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged
Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit
Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies
Addition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience
Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report
Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report